Top Cited Articles

Immune-related adverse events and anti-tumor efficacy of immune checkpoint inhibitors
Das, Satya; Johnson, Douglas B.

The role of PD-L1 expression as a predictive biomarker: an analysis of all US Food and Drug Administration (FDA) approvals of immune checkpoint inhibitors
Davis, Andrew A.; Patel, Vaibhav G.

Consensus guidelines for the definition, detection and interpretation of immunogenic cell death (vol 8, e000337, 2020)
Galluzzi, Lorenzo; Vitale, Ilio; Warren, Sarah et al

The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of squamous cell carcinoma of the head and neck (HNSCC)
Cohen, Ezra E. W.; Bell, R. Bryan; Bifulco, Carlo B. et al

Mechanisms regulating PD-L1 expression on tumor and immune cells
Chen, Shuming; Crabill, George A.; Pritchard, Theresa S. et al

Final analyses of OPTiM: a randomized phase III trial of talimogene laherparepvec versus granulocyte-macrophage colony-stimulating factor in unresectable stage III- IV melanoma
Andtbacka, Robert H., I; Collichio, Frances; Harrington, Kevin J. et al

A multicenter study of body mass index in cancer patients treated with anti-PD-1/PD-L1 immune checkpoint inhibitors: when overweight becomes favorable
Cortellini, Alessio; Bersanelli, Melissa; Buti, Sebastiano et al

Exploring the emerging role of the microbiome in cancer immunotherapy
Fessler, Jessica; Matson, Vyara; Gajewski, Thomas F.

Phase 2 study of pembrolizumab in patients with advanced rare cancers
Naing, Aung; Meric-Bernstam, Funda; Stephen, Bettzy et al

A first-in-human phase 1 dose escalation study of spartalizumab (PDR001), an anti-PD-1 antibody, in patients with advanced solid tumors
Naing, Aung; Gainor, Justin F.; Gelderblom, Hans et al

Small molecule immunomodulation: the tumor microenvironment and overcoming immune escape
Osipov, Arsen; Saung, May Tun; Zheng, Lei et al

Correlation of plasma exosomal microRNAs with the efficacy of immunotherapy in EGFR/ALK wild-type advanced non-small cell lung cancer
Peng, Xiao-Xiao; Yu, Ruoying; Wu, Xue et al

Lymphopenia in Cancer Patients and its Effects on Response to Immunotherapy: an opportunity for combination with Cytokines?
Menetrier-Caux, Christine; Ray-Coquard, Isabelle; Blay, Jean-Yves et al

Immunosuppression by monocytic myeloid-derived suppressor cells in patients with pancreatic ductal carcinoma is orchestrated by STAT3
Trovato, Rosalinda; Fiore, Alessandra; Sartori, Sara et al

The Society for Immunotherapy of Cancer perspective on regulation of interleukin-6 signaling in COVID-19-related systemic inflammatory response
Arnaldez, Fernanda, I; O’Day, Steven J.; Drake, Charles G. et al

Identification of tumor immune infiltration-associated lncRNAs for improving prognosis and immunotherapy response of patients with non-small cell lung cancer
Sun, Jie; Zhang, Zicheng; Bao, Siqi et al

Dual targeting of TGF-beta and PD-L1 via a bifunctional anti-PD-L1/TGF-beta RII agent: status of preclinical and clinical advances
Lind, Hanne; Gameiro, Sofia R.; Jochems, Caroline et al

Tim-3 finds its place in the cancer immunotherapy landscape
Acharya, Nandini; Sabatos-Peyton, Catherine; Anderson, Ana Carrizosa

Serum interleukin-6 and C-reactive protein are associated with survival in melanoma patients receiving immune checkpoint inhibition
Laino, Andressa S.; Woods, David; Vassallo, Melinda et al

Differential expansion of circulating human MDSC subsets in patients with cancer, infection and inflammation
Cassetta, Luca; Bruderek, Kirsten; Skrzeczynska-Moncznik, Joanna et al